운전자본 팽창 → 현금 고갈 → 유동성 위기
Warning순운전자본이 +24.6% 팽창하며 현금이 묶이고 있다. 영업CF/순이익 비율이 -58%로 이익 대비 현금 회수가 부족하고, 유동비율도 12.27에서 11.90로 하락했다.
Evidence
순운전자본 YoY +24.6%영업CF/순이익 -58%유동비율 12.27→11.90
Agios Pharmaceuticals
AGIO · Nasdaq$33.10-0.09%
2026-09-04 closeAgios Pharmaceuticals last closed at $33.10 (-0.09%) on 2026-09-04. Listed on Nasdaq; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
277 picks
Next-day win rate
44.2%
Avg next-day
-0.28%
vs market
-0.51%p
Every new-high-plus-volume pick we actually published (US market) — not this stock alone.
Signal history
| Date | Signal | +20 trading days |
|---|---|---|
A record, not a prediction.
How this is calculated
"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
A-
Overall: 건강관리 163/745 · top 22%
Factor composite · relative position in sector
PER 2.86 · PBR 1.25 — own-history percentile 89/100 · 86/100
Open self-history band
PER89/100
PBR86/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 19.11
Distress
Grey
Safe
- Altman Z''
- 19.11
- Beneish M-Score
- 2.32
- Sloan accrual
- 63.95%
Statistical manipulation-risk signal
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
4/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score4/9
Profitability
- Positive ROAPass
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtPass
- Higher current ratioNot passed
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -1068%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
USAs of 2026-09-05건강관리
This stock is in 건강관리: revenue rank 352 of 543, share 0%.
352 / 5430%revenue share
Who dominates this industry?
- 1CVS Health14.1%
- 2McKesson13.6%
- 3Cigna9.4%
- 4Cardinal Health8.4%
- 5Centene6.2%
- 6Agios Pharmaceuticals0%
Concentration
DistributedCR3 37.1%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 159.97
- Direction
- 축소
- Level
- 넓음
- Years
- 21
Value lens
- P90/P10
- 24.4
- Median P/B
- 3.02
- Level
- 넓음
- n
- 463
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 1,817.6%
- Interest coverage
- 64.2x
- Return on equity (ROE)
- 43.7%
Operating margin −5pp
TolerableInterest coverageBase 64.2x adverse case 64.1x
Return on equity (ROE)Base 43.7% adverse case 42.3%
Revenue −15%
TolerableInterest coverageBase 64.2x adverse case 54.6x
Return on equity (ROE)Base 43.7% adverse case 35.9%
Interest rate +2pp
TolerableInterest coverageBase 64.2x adverse case 51.9x
Return on equity (ROE)Base 43.7% adverse case 42.2%
Interest coverage limit
Current margin 1,789.3ppInterest coverage limit at an operating margin of 28.3%
Interest expense coverage threshold
Connections
AI-extracted related companies · for reference
Customers
ServierSanofi
Competitors
Same theme
FDANCCN
Recent filings
Filings for overseas stocks are on the way. For now we cover Korean stocks only.
About Agios Pharmaceuticals
- What technical signals does Agios Pharmaceuticals (AGIO) have?
- Agios Pharmaceuticals current technical signals: no active technical signal.
- Is Agios Pharmaceuticals a cup-and-handle pattern?
- No. Agios Pharmaceuticals has no valid cup-and-handle signal right now.
- What are Agios Pharmaceuticals's financials and valuation?
- Agios Pharmaceuticals's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy